Avara Pharmaceutical expands into Canadian market with acquisition of sterile manufacturing facility

Avara Pharmaceutical expands into Canadian market with acquisition of sterile manufacturing facility

Avara Pharmaceutical Services, a prominent US-based contract development and manufacturing organization (CDMO), has successfully completed the acquisition of a sterile manufacturing facility for injectable medicines located in Boucherville, Quebec. This strategic acquisition, initially announced in late May 2018, marks Avara’s first foray into the Canadian market and significantly enhances its capabilities in sterile processing. The […]

EC approves Novartis’ skin cancer therapy combo Tafinlar and Mekinist for melanoma

EC approves Novartis’ skin cancer therapy combo Tafinlar and Mekinist for melanoma

In a significant development for melanoma treatment, the European Commission (EC) has granted Novartis approval for its combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib). This approval is specifically for adjuvant therapy in stage III melanoma patients who are positive for the BRAF V600 mutation and have undergone complete surgical resection. The approval is based […]

Novartis reveals positive results from Entresto Phase 4 TRANSITION study for heart failure patients

Novartis reveals positive results from Entresto Phase 4 TRANSITION study for heart failure patients

Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in a broad range of patients with heart failure with reduced ejection fraction (HFrEF), shortly after stabilization from an acute heart failure episode. This groundbreaking study underlines the effectiveness of Entresto […]

Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas

Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas

In a significant advancement for biopharmaceuticals, Novartis’ division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. This approval encompasses all indications of the reference drug, including treatment for rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis, and ulcerative colitis, marking a pivotal step in broadening access to […]

Novartis secures global rights to atopic dermatitis drug MOR106

Novartis secures global rights to atopic dermatitis drug MOR106

In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive global development and marketing rights for the atopic dermatitis drug, MOR106. This deal, potentially worth up to $1.1 billion, underscores Novartis’ commitment to advancing care in immuno-dermatology. Under the terms […]

Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio

Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio

Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic move is set to enhance Novartis’s capabilities in gene therapy and neuroscience, particularly in the treatment of spinal muscular atrophy (SMA). Strategic Acquisition in Pharma Under the agreement, Novartis will […]

GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn

GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn

In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis’ 36.5% stake in their consumer healthcare joint venture for $13 billion. This move comes shortly after GSK withdrew from a $20 billion bid to purchase Pfizer’s consumer healthcare business, indicating a focused realignment of GSK’s investment towards owning 100% of its […]

Novartis to acquire Advanced Accelerator Applications for $3.9bn to enhance oncology portfolio

Novartis to acquire Advanced Accelerator Applications for $3.9bn to enhance oncology portfolio

Novartis, the Switzerland-based global healthcare giant, has announced its decision to acquire Advanced Accelerator Applications (AAA), a French radiopharmaceutical company, for $3.9 billion. This acquisition is aimed at bolstering Novartis’ oncology platform, with a focus on expanding its portfolio with innovative nuclear medicine treatments. Details of the Acquisition and Expected Benefits Novartis will purchase all […]

FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer

Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions.

FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer

Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority review by the U.S. Food and Drug Administration (FDA) for its expanded use in treating lung cancer. This priority review specifically targets its application as a first-line treatment for patients […]

1 4 5 6